These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 27570458)

  • 1. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
    Pinilla-Ibarz J; Sweet KL; Corrales-Yepez GM; Komrokji RS
    Onco Targets Ther; 2016; 9():4937-57. PubMed ID: 27570458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
    Bisen A; Claxton DF
    Adv Exp Med Biol; 2013; 779():179-96. PubMed ID: 23288640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.
    Vainchenker W; Leroy E; Gilles L; Marty C; Plo I; Constantinescu SN
    F1000Res; 2018; 7():82. PubMed ID: 29399328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.
    Sonbol MB; Firwana B; Zarzour A; Morad M; Rana V; Tiu RV
    Ther Adv Hematol; 2013 Feb; 4(1):15-35. PubMed ID: 23610611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?
    Sora F; Chiusolo P; Autore F; Giammarco S; Laurenti L; Innocenti I; Metafuni E; Galli E; Bacigalupo A; Sica S
    Mediterr J Hematol Infect Dis; 2021; 13(1):e2021062. PubMed ID: 34804436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-occurrence of
    Zanelli M; Bisagni A; Sanguedolce F; Broggi G; Fragliasso V; Zizzo M; Palicelli A; Martino G; Cresta C; Caprera C; Corsi M; Gentile P; Gozzi F; Trombetta D; Parente P; Caltabiano R; Koufopoulos N; Cimino L; Cavazza A; Fraternali Orcioni G; Ascani S
    Front Oncol; 2023; 13():1329298. PubMed ID: 38282677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Lewandowski K; Gniot M; Wojtaszewska M; Kanduła Z; Becht R; Paczkowska E; Mędraś E; Wasilewska E; Iwoła M
    Int J Lab Hematol; 2018 Jun; 40(3):366-371. PubMed ID: 29508552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.
    Oh ST
    Ther Adv Hematol; 2011 Feb; 2(1):11-9. PubMed ID: 23556072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease modifying agents of myeloproliferative neoplasms: a review.
    Lee SE
    Blood Res; 2021 Apr; 56(S1):S26-S33. PubMed ID: 33935032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
    Singdong R; Siriboonpiputtana T; Chareonsirisuthigul T; Kongruang A; Limsuwanachot N; Sirirat T; Chuncharunee S; Rerkamnuaychoke B
    Asian Pac J Cancer Prev; 2016 Oct; 17(10):4647-4653. PubMed ID: 27892678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
    Masarova L; Bose P; Verstovsek S
    Curr Hematol Malig Rep; 2019 Aug; 14(4):310-327. PubMed ID: 31228096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.
    Verma T; Papadantonakis N; Peker Barclift D; Zhang L
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
    Treliński J; Robak T
    Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
    Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
    Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
    Rosenthal A; Mesa RA
    Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.
    Reuther GW
    Prog Mol Biol Transl Sci; 2016; 144():437-484. PubMed ID: 27865464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK-mutant myeloproliferative neoplasms.
    Levine RL
    Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AXL Inhibition Represents a Novel Therapeutic Approach in
    Beitzen-Heineke A; Berenbrok N; Waizenegger J; Paesler S; Gensch V; Udonta F; Vargas Delgado ME; Engelmann J; Hoffmann F; Schafhausen P; von Amsberg G; Riecken K; Beumer N; Imbusch CD; Lorens J; Fischer T; Pantel K; Bokemeyer C; Ben-Batalla I; Loges S
    Hemasphere; 2021 Sep; 5(9):e630. PubMed ID: 34396051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.